Skip to navigation Skip to content

Primary hyperoxaluria type 1 (PH1) Program in Pharmaceutical Benefits Scheme (PBS) 012-25090506

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised lumasiran for patients with primary hyperoxaluria type 1 (PH1).

PH1 and listing dates

PH1 is a rare genetic disorder causing high oxalate levels in urine, leading to kidney stones and potential kidney failure.

Listing date: lumasiran - 1 October 2025.

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs and choose the option relevant to the condition treated.

The Resources page contains:

  • application forms
  • contact details
  • FAQs from Service Officers
  • restriction and item codes
  • the PBS schedule
  • Services Australia website link

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing Delayed Assessment requests in the Pharmaceutical Benefits Scheme (PBS)

Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS)

Written Authority Required Drugs